← Back to Search

Disinfectant

Alcohol for Skin Infections

Phase 3
Waitlist Available
Led By Anna Taddio, PhD
Research Sponsored by University of Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* healthy pediatric patients undergoing routine vaccinations
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from date of first enrollment until the date of final enrollment, up to 1 year
Awards & highlights
Pivotal Trial
Approved for 5 Other Conditions
All Individual Drugs Already Approved

Summary

Alcohol is used to disinfect the skin prior to injections in order to prevent infections caused by bacteria on the skin being injected within tissue. At present, however, clinical trials do not demonstrate a clinical impact of using or not using alcohol swabs on infections and infection symptoms calling into question the practice of using it prior to all injections. These studies are methodologically flawed, and do not specifically examine vaccine injections. The present study is being undertaken to provide some preliminary data for the risk of infection and infection symptoms when alcohol swabs are not used to perform vaccine injections.

Eligible Conditions
  • Skin Infections

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from date of first enrollment until the date of final enrollment, up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and from date of first enrollment until the date of final enrollment, up to 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Skin infection
Secondary study objectives
Compliance with protocol
Feasibility of protocol
Feasibility of recruitment
+1 more

Side effects data

From 2017 Phase 2 trial • 17 Patients • NCT01779024
59%
Increased Appetite
41%
Somnolence
35%
Euphoric mood
29%
Fatigue
12%
Hyperhidrosis
12%
Memory impairment
12%
Dizziness
12%
Nausea
6%
Feeling hot
6%
Flushing
6%
Headache
6%
Decreased appetite
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ghrelin
Placebo

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AlcoholExperimental Treatment1 Intervention
Alcohol will be wiped on the vaccine injection site immediately before vaccine injection.
Group II: No alcoholPlacebo Group1 Intervention
Alcohol will be wiped adjacent to the vaccine injection site immediately before vaccine injection.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ethanol
FDA approved

Find a Location

Who is running the clinical trial?

University of TorontoLead Sponsor
714 Previous Clinical Trials
1,022,652 Total Patients Enrolled
Anna Taddio, PhDPrincipal InvestigatorUniversity of Toronto
17 Previous Clinical Trials
19,010 Total Patients Enrolled
~20 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top